GuidelineBreast (Edinburgh, Scotland)2022
Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL.
Guideline in Breast (Edinburgh, Scotland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- The impact of breast cancer on cosmetic breast augmentation outcomes and screening challenges in patients with implants: a literature review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Ultrasound Elastography and Tonometry as Predictive Tools for Capsular Contracture After Breast Implant Surgery: Over a 12-Month Prospective Study.Journal of clinical medicine · 2025Article
- High-Quality, Safe, and Accessible Free Care for BIA-ALCL Patients Within the Italian Public Healthcare System.Aesthetic plastic surgery · 2025Article
- Smooth Breast Implants Should Be Available to Women Diagnosed with BIA-ALCL.Aesthetic plastic surgery · 2025Article
- Lateral Flow Assay to Detect Carbonic Anhydrase IX in Seromas of Breast Implant-Associated Anaplastic Large Cell Lymphoma.Cancers · 2025Article
- Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.International journal of molecular sciences · 2025Review
- Conflict of Interest and Recommendations for Explantation in Asymptomatic Patients Concerned About BIA-ALCL Risk.Annals of plastic surgery · 2025Article
- Current Knowledge on Breast Implant-Associated Anaplastic Large Cell Lymphoma: Evidence from Italian Ministry of Health Registry Data.Aesthetic plastic surgery · 2025Article
- Application of Ultrasound Radiomics in Differentiating Benign from Malignant Breast Nodules in Women with Post-Silicone Breast Augmentation.Current oncology (Toronto, Ont.) · 2025Article
- The Lipo-DIEP Flap Breast Reconstruction: A Valuable Innovation for Maximizing Abdominal Tissue Volume.Plastic and reconstructive surgery. Global open · 2025Article
- Anaplastic Large Cell Lymphoma Related to Breast Implant Presenting as a Solid mass: A Case Report.Case reports in surgery · 2025Article
- Silicone Breast Implant Rupture Triggered by Infection Leading to Skin Ulceration: A Case Report.Cureus · 2024Article
- Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report About a Patient with Cytology Negative for Malignancy.Life (Basel, Switzerland) · 2024Article
- Article
- A case of BIA-ALCL in which postoperative chest wall recurrence was highly suspected: the third reported case of BIA-ALCL in Japan.Surgical case reports · 2024Article
- BIA-ALCL and BIA-SCC: Updates on Clinical Features and Genetic Mutations for Latest Recommendations.Medicina (Kaunas, Lithuania) · 2024Review
- Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report about a Male Patient with Pectoral Implants.Breast care (Basel, Switzerland) · 2024Article
- Comment on "BIA-ALCL: Comparing the Risk Profiles of Smooth and Textured Breast Implants".Aesthetic plastic surgery · 2024Article
- Reply: Comment on BIA-ALCL: Comparing the Risk Profiles of Smooth and Textured Breast Implants.Aesthetic plastic surgery · 2024Article
- Oncological Outcomes After Multidisciplinary Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).Annals of surgical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shared strategies and correct information are essential to guide physicians in the management of such an uncommon disease as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). A systematic review of the literature was performed to collect the most relevant evidence on BIA-ALCL reported cases. A panel of multidisciplinary experts discussed the scientific evidence on BIA-ALCL, and updated consensus recommendations were developed through the Delphi process. The lastest reported Italian incidence of BIA-ALCL is 3.5 per 100.000 implanted patients (95% CI, 1.36 to 5.78), and the disease counts over 1216 cases worldwide as of June 2022. The most common presentation symptom is a late onset seroma followed by a palpable breast mass. In the event of a suspicious case, ultrasound-guided fine-needle aspiration should be the first step in evaluation, followed by cytologic and immunohistochemical examination. In patients with confirmed diagnosis of BIA-ALCL confined to the capsule, the en-bloc capsulectomy should be performed, followed by immediate autologous reconstruction, while delayed reconstruction applies for disseminate disease or radically unresectable tumor. Nevertheless, a multidisciplinary team approach is essential for the correct management of this pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.